- Home
- HUCK vs CHRS Comparison
HUCK vs CHRS Comparison
Compare HUCK & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$3.15
BUY
Current Price
$1.07
Company Overview
Basic Information| Metric | HUCK | CHRS |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 177.7M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HUCK | CHRS |
|---|---|---|
| Price | $3.15 | $1.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.17 | ★ $7.75 |
| AVG Volume (30 Days) | 666.0K | ★ 1.3M |
| Earning Date | 09-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.92 | ★ 472.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,857,000.00 | N/A |
| Revenue This Year | N/A | $44.19 |
| Revenue Next Year | $1.33 | $65.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.16 | $1.08 |
| 52 Week High | $3.45 | $2.62 |
Technical Indicators
Market Signals| Indicator | HUCK | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 16.33 | 35.53 |
| Support Level | N/A | N/A |
| Resistance Level | $3.45 | $1.53 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 10.23 | 6.41 |
Price Performance
Historical Comparison HUCK
CHRS
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.